Elanco Animal Health Inc
About Elanco Animal Health Inc
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $4.7B
- Net income
- -$232.0M
- Total assets
- $13.4B
- Market cap
- $11.8B
- Gross margin
- 55.0%
- Operating margin
- -4.8%
- Net margin
- -4.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.7B
- Cost of revenue
- $2.1B
- Gross profit
- $2.6B
- Operating expenses
- $2.8B
- Operating income
- -$224.0M
- Income tax
- $8.0M
- Net income
- -$232.0M
- EPS (basic)
- $-0.47
- EPS (diluted)
- $-0.47
Balance sheet
- Total assets
- $13.4B
- Current assets
- $3.5B
- Total liabilities
- $6.8B
- Current liabilities
- $1.6B
- Shareholders’ equity
- $6.5B
Cash flow
- Operating cash flow
- $560.0M
- Investing cash flow
- -$279.0M
- Financing cash flow
- -$275.0M
- Net cash flow
- $77.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $11.8B
- EPS (diluted)
- $-0.47
- Shares outstanding
- 498.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 20, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $232.0M in FY2025.
- Revenue declined 1% from FY2021 to FY2025.
- Gross margin of 55.0%, net margin -4.9%.
- Trading 12% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Elanco Animal Health Inc.
Write a review
News about Elanco Animal Health Inc
News & sentiment via Polygon.io
